{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/108097"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/108097","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Analytical validation and evaluation of the effects of intramuscular injections on acute phase proteins in horses","abstract":"Acute phase protein (APP) measurement can be used to characterize and detect inflammation, as well as monitor response to therapy. Intramuscular (IM) injections often result in local swelling and inflammation, which may lead to increased plasma concentrations of APP. The first objective of this study was to determine whether equine plasma haptoglobin (HAP) concentrations could be measured reliably with an immunoturbidimetric assay developed for use in humans. Within run and between run imprecisions were evaluated by multiple measurements of equine plasma samples with high, intermediate, and low HAP concentrations. Assay inaccuracy was determined by linearity under dilution. In plasma samples with high, intermediate, and low HAP concentrations, the within run imprecisions were 3.13%, 1.89%, and 1.76%, and the between run imprecisions were 2.77%, 1.45%, and 1.21%. Acceptable linearity within a range of 7-122 mg/dL was observed. The detection limit was 0 mg/dL. No clinically significant interference was observed from hemoglobin, lipids, or bilirubin. In conclusion, equine HAP concentrations can be measured reliably up to 122 mg/dL using the immunoturbidimetric assay designed for human HAP. The second objective was to evaluate the possible effects of IM procaine penicillin G (PPG) injections on plasma concentrations of selected APP, including fibrinogen (FIB), serum amyloid A (SAA), and HAP, as well as on the activity of selected enzymes, including creatine kinase (CK) and aspartate aminotransferase (AST). The plasma concentrations of the aforementioned variables were evaluated for 5 consecutive days prior to drug administration (days -5 to -1), during a 5-day course of PPG administered twice daily at a recommended therapeutic dose (days 0 to 4), and for 20 days following the final injection (days 5 to 24). Results showed a significant increase in CK activity on days 1-6 and an increase in AST activity on days 2-7 and 10. A significant increase in plasma FIB was noted on days 6-8 and 10, and SAA on day 6. No significant changes in HAP were observed. These findings indicate that muscle injury caused by PPG injections may result in increased CK and AST activity and increased plasma concentration of a subset of APP including FIB and SAA.","abstract_html":"Acute phase protein (APP) measurement can be used to characterize and detect inflammation, as well as monitor response to therapy. Intramuscular (IM) injections often result in local swelling and inflammation, which may lead to increased plasma concentrations of APP. The first objective of this study was to determine whether equine plasma haptoglobin (HAP) concentrations could be measured reliably with an immunoturbidimetric assay developed for use in humans. Within run and between run imprecisions were evaluated by multiple measurements of equine plasma samples with high, intermediate, and low HAP concentrations. Assay inaccuracy was determined by linearity under dilution. In plasma samples with high, intermediate, and low HAP concentrations, the within run imprecisions were 3.13%, 1.89%, and 1.76%, and the between run imprecisions were 2.77%, 1.45%, and 1.21%. Acceptable linearity within a range of 7-122 mg/dL was observed. The detection limit was 0 mg/dL. No clinically significant interference was observed from hemoglobin, lipids, or bilirubin. In conclusion, equine HAP concentrations can be measured reliably up to 122 mg/dL using the immunoturbidimetric assay designed for human HAP. The second objective was to evaluate the possible effects of IM procaine penicillin G (PPG) injections on plasma concentrations of selected APP, including fibrinogen (FIB), serum amyloid A (SAA), and HAP, as well as on the activity of selected enzymes, including creatine kinase (CK) and aspartate aminotransferase (AST). The plasma concentrations of the aforementioned variables were evaluated for 5 consecutive days prior to drug administration (days -5 to -1), during a 5-day course of PPG administered twice daily at a recommended therapeutic dose (days 0 to 4), and for 20 days following the final injection (days 5 to 24). Results showed a significant increase in CK activity on days 1-6 and an increase in AST activity on days 2-7 and 10. A significant increase in plasma FIB was noted on days 6-8 and 10, and SAA on day 6. No significant changes in HAP were observed. These findings indicate that muscle injury caused by PPG injections may result in increased CK and AST activity and increased plasma concentration of a subset of APP including FIB and SAA.","abstract_has_math":false,"creators":["Gordon, Danielle Louise"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"M.S.","degree_level":"Thesis","degree_discipline":"VMS-Veterinary Clinical Medcne","degree_department":null,"school":null,"contributors":["Foreman, Jonathan H","Barger, Anne M","Schnelle, Amy N","Connolly, Sara L","Fan, Timothy M"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-08-26T23:51:26Z","date_published":"2020-08-26T23:51:26Z","updated_at":"2026-07-22T22:24:47Z","subjects":["Acute phase protein","Acute phase response","equine","horse","inflammation","intramuscular injection","method validation"],"languages":["en"],"rights":["Copyright 2020 Danielle Gordon"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/108097","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Foreman, Jonathan H","Barger, Anne M","Schnelle, Amy N","Connolly, Sara L","Fan, Timothy M"]},{"key":"dc:creator","label":"Author","values":["Gordon, Danielle Louise"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-08-26T23:51:26Z","2022-08-26T23:58:55Z","2020-03-30","2020-05"]},{"key":"dc:type","label":"Dc Type","values":["text","Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["VMS-Veterinary Clinical Medcne"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Acute phase protein","Acute phase response","equine","horse","inflammation","intramuscular injection","method validation"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2020 Danielle Gordon"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/108097"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Acute phase protein (APP) measurement can be used to characterize and detect inflammation, as well as monitor response to therapy. Intramuscular (IM) injections often result in local swelling and inflammation, which may lead to increased plasma concentrations of APP. The first objective of this study was to determine whether equine plasma haptoglobin (HAP) concentrations could be measured reliably with an immunoturbidimetric assay developed for use in humans. Within run and between run imprecisions were evaluated by multiple measurements of equine plasma samples with high, intermediate, and low HAP concentrations. Assay inaccuracy was determined by linearity under dilution. In plasma samples with high, intermediate, and low HAP concentrations, the within run imprecisions were 3.13%, 1.89%, and 1.76%, and the between run imprecisions were 2.77%, 1.45%, and 1.21%. Acceptable linearity within a range of 7-122 mg/dL was observed. The detection limit was 0 mg/dL. No clinically significant interference was observed from hemoglobin, lipids, or bilirubin. In conclusion, equine HAP concentrations can be measured reliably up to 122 mg/dL using the immunoturbidimetric assay designed for human HAP. The second objective was to evaluate the possible effects of IM procaine penicillin G (PPG) injections on plasma concentrations of selected APP, including fibrinogen (FIB), serum amyloid A (SAA), and HAP, as well as on the activity of selected enzymes, including creatine kinase (CK) and aspartate aminotransferase (AST). The plasma concentrations of the aforementioned variables were evaluated for 5 consecutive days prior to drug administration (days -5 to -1), during a 5-day course of PPG administered twice daily at a recommended therapeutic dose (days 0 to 4), and for 20 days following the final injection (days 5 to 24). Results showed a significant increase in CK activity on days 1-6 and an increase in AST activity on days 2-7 and 10. A significant increase in plasma FIB was noted on days 6-8 and 10, and SAA on day 6. No significant changes in HAP were observed. These findings indicate that muscle injury caused by PPG injections may result in increased CK and AST activity and increased plasma concentration of a subset of APP including FIB and SAA.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2022-05-01","The student, Danielle Gordon, accepted the attached license on 2020-03-27 at 09:46.","The student, Danielle Gordon, submitted this Thesis for approval on 2020-03-27 at 09:54.","This Thesis was approved for publication on 2020-03-30 at 15:39.","DSpace SAF Submission Ingestion Package generated from Vireo submission #14917 on 2020-08-25 at 17:27:11","Made available in DSpace on 2020-08-26T23:51:26Z (GMT). No. of bitstreams: 2 GORDON-THESIS-2020.pdf: 1634031 bytes, checksum: 2e0d6c7411cf9669effe5d738c7318cd (MD5) LICENSE.txt: 4212 bytes, checksum: e50682ae6e669f5ad025c9c5439d837a (MD5) Previous issue date: 2020-03-30","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:51:32Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:54:40Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:55:59Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:57:28Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:58:55Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Analytical validation and evaluation of the effects of intramuscular injections on acute phase proteins in horses"]}]}],"canonical_facts":{"dc:contributor":["Foreman, Jonathan H","Barger, Anne M","Schnelle, Amy N","Connolly, Sara L","Fan, Timothy M"],"dc:creator":["Gordon, Danielle Louise"],"dc:date":["2020-08-26T23:51:26Z","2022-08-26T23:58:55Z","2020-03-30","2020-05"],"dc:description":["Acute phase protein (APP) measurement can be used to characterize and detect inflammation, as well as monitor response to therapy. Intramuscular (IM) injections often result in local swelling and inflammation, which may lead to increased plasma concentrations of APP. The first objective of this study was to determine whether equine plasma haptoglobin (HAP) concentrations could be measured reliably with an immunoturbidimetric assay developed for use in humans. Within run and between run imprecisions were evaluated by multiple measurements of equine plasma samples with high, intermediate, and low HAP concentrations. Assay inaccuracy was determined by linearity under dilution. In plasma samples with high, intermediate, and low HAP concentrations, the within run imprecisions were 3.13%, 1.89%, and 1.76%, and the between run imprecisions were 2.77%, 1.45%, and 1.21%. Acceptable linearity within a range of 7-122 mg/dL was observed. The detection limit was 0 mg/dL. No clinically significant interference was observed from hemoglobin, lipids, or bilirubin. In conclusion, equine HAP concentrations can be measured reliably up to 122 mg/dL using the immunoturbidimetric assay designed for human HAP. The second objective was to evaluate the possible effects of IM procaine penicillin G (PPG) injections on plasma concentrations of selected APP, including fibrinogen (FIB), serum amyloid A (SAA), and HAP, as well as on the activity of selected enzymes, including creatine kinase (CK) and aspartate aminotransferase (AST). The plasma concentrations of the aforementioned variables were evaluated for 5 consecutive days prior to drug administration (days -5 to -1), during a 5-day course of PPG administered twice daily at a recommended therapeutic dose (days 0 to 4), and for 20 days following the final injection (days 5 to 24). Results showed a significant increase in CK activity on days 1-6 and an increase in AST activity on days 2-7 and 10. A significant increase in plasma FIB was noted on days 6-8 and 10, and SAA on day 6. No significant changes in HAP were observed. These findings indicate that muscle injury caused by PPG injections may result in increased CK and AST activity and increased plasma concentration of a subset of APP including FIB and SAA.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2022-05-01","The student, Danielle Gordon, accepted the attached license on 2020-03-27 at 09:46.","The student, Danielle Gordon, submitted this Thesis for approval on 2020-03-27 at 09:54.","This Thesis was approved for publication on 2020-03-30 at 15:39.","DSpace SAF Submission Ingestion Package generated from Vireo submission #14917 on 2020-08-25 at 17:27:11","Made available in DSpace on 2020-08-26T23:51:26Z (GMT). No. of bitstreams: 2 GORDON-THESIS-2020.pdf: 1634031 bytes, checksum: 2e0d6c7411cf9669effe5d738c7318cd (MD5) LICENSE.txt: 4212 bytes, checksum: e50682ae6e669f5ad025c9c5439d837a (MD5) Previous issue date: 2020-03-30","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:51:32Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:54:40Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:55:59Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:57:28Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 115706 Lift date: 2022-08-26T23:58:55Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only"],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/108097"],"dc:language":["en"],"dc:rights":["Copyright 2020 Danielle Gordon"],"dc:subject":["Acute phase protein","Acute phase response","equine","horse","inflammation","intramuscular injection","method validation"],"dc:title":["Analytical validation and evaluation of the effects of intramuscular injections on acute phase proteins in horses"],"dc:type":["text","Thesis"],"thesis:degree_discipline":["VMS-Veterinary Clinical Medcne"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["M.S."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:47Z"}